The Bangladesh Securities Exchange Commission (BSEC) approved IPO “Indo Bangla Pharmaceuticals Ltd.” on Tuesday, 3rd October 2017 at their 613 nos Board Meeting. Presided by BSEC Chairman Prof. Dr M Khairul Hossain to issue 2.00 crore ordinary shares worth Tk 10 each. Company Information, IPO Application Form, Prospectus & Result is given below:
Indo-Bangla Pharmaceuticals Ltd., the flagship company of IBP group was established in 1954, incorporated as a private limited company under the Companies Act on June 18, 2014, and converted into a public limited company on October 21, 2014. From the inception in 1954 Indo-Bangla Pharmaceuticals Ltd. has stood for quality, business success and responsible entrepreneurship.
NATURE OF BUSINESS:
Healthcare is one of the important factors among the fundamental need of human being. Since the established of Indo-Bangla Pharmaceuticals Ltd., it has been aiming to fulfil this fundamental demand of the people of Bangladesh and is committed to reaching the healthcare service to the doorstep of the common people and all over the world. IBPL believe that the experience and skill of the physician supported with quality medicines can only ensure better human life.
IBPL are an ISO 9001:2008 certified company and committed to improving the quality of human life by enabling people to do more, feel better and live longer. IBPL also believe and adhere to values like Quality, Knowledge and Responsibility in all aspects of its operation and earned respect and recognition of its valued customers in the healthcare sector of Bangladesh.
There are many medicine produce by IBPL but for your kind information here ten approved Products given below:
- Tablet I–Cet -10mg
- Tablet Trialugel – 250mg & 400mg
- Tablet Indomol Plus -500mg & 65mg
- Tablet Indo-Fila 100mg
- Tablet Indosin
- Tablet I-Fol
- Tablet I-Fol Plus
- Tablet Mebendox 100mg
- Tablet Albendox 400mg
- Tablet Sulbumol 2.0mg
Corporate Office: House#11/1, Jahan Tower Flat-B2(2nd Floor), Road: Murad Sarak, Avoy Das lane, Dhaka-1203.
Registered Office & Factory: Add-Aziz Bhaban, H/N:0729-000,
College Road, Barisal Sadar, Barisal-8200.
Phone: +88 0431 2174811, +88 0431 2174977
Fax: ++88-02-57164716 (Ext-101)
Email: [email protected]
Web Address: www.indo-banglapharma.com
TWO YEAR MAJOR FINANCIAL INFORMATION AS FOLLOWS:
|Net Profit before tax||90,807,238||92,629,642|
|Net Profit after tax||59,024,705||60,209,267|
|No. of Shares||73,000,000||9,900,000|
|NAV per Shares||11.63||16.08|
|Earnings per Share (Basic)||2.62||6.40|
INDO BANGLA PHARMACEUTICALS LTD. EPS & NAV:
As per company’s year ended financial statement on 30 June 2016, Indo Bangla Pharmaceuticals Ltd. stands Net Assets Value per shares Tk. 11.63 and Earning Per Shares (EPS) at Tk. 2.62.
AFC Capital Ltd., EBL Investment Ltd. and CAPM Advisory Ltd. are jointly working as the manager to the issue.
WHY PUBLIC OFFERING:
Bangladesh Securities Exchange Commission (BSEC) approved IPO of above Co. on 3 October 2017. The companies will raise a fund worth Tk. 200.00 million for the purpose of acquisition of Plant & Machinery and Construction of the new factory building, Administration building, Go-down, Garaged and IPO expenses meet from IPO proceeds.
NOS. OF SHARE OFFER: 20,000,000
VALUE OF IPO: Tk. 200,000,000/=
FACE VALUE: Tk. 10/=
PREMIUM VALUE: Nil
MINIMUM LOT VALUE: Tk.5000.-
SHARE ALLOTMENT: 40% for General Public and Affected Investors=16,000 lot, 40% for Eligible Investor (EI) =16,000 lot, 10% for NRB = 4,000 lot and 10% for Mutual Fund = 4,000 lot.
** The Company will collect IPO money through BSEC new rules and the new rule is “BROKER HOUSE SHOULD COLLECT IPO MONEY ONLY”.
The Company’s subscription date and Final Prospectus will publish very soon.
DOWNLOAD IPO FORM HERE:
INDO BANGLA PHARMACEUTICALS LTD.: DRAFT PROSPECTUS
DOWNLOAD LOTTERY RESULT HERE:
YET TO BE PUBLISHED
Stock Broker / Merchant Bank Code
Non-Residence Bangladeshi (NRB)
THANK YOU FOR VISITING HITBANGLA.COM.
Incoming search terms:
indo bangla pharmaceutical ipo, nrb pharmaceutical